Skip to main content

Table 2 Methotrexate history of study patients

From: Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life

Age in years at starting MTX, mean (S.D.) (n=168) 6.1 (3.9)
Duration in months of MTX use, median (IQR) 29.0 (11.5 – 60.5)
Current MTX dose (mg/m2/week), median (IQR) 12.5 (10 – 15)
MTX route, n (%)  
Oral route throughout 55 (32.2)
Current route oral but previously subcutaneous 16 (9.4)
Subcutaneous route throughout 24 (14.0)
Current route subcutaneous but previously oral 76 (44.4)